Citations

Showing 10 of 108081 citations.

Anatomical Step-by-Step Dissection of Complex Skull Base Approaches for Trainees: Surgical Anatomy of the Endoscopic Endonasal Clivectomy, Odontoidectomy, and Far Medial Approach
Agosti, Edoardo, Yohan, Alex Y., Leonel, Luciano, Peris‐Celda, Maria , Agosti, Edoardo , Pinheiro‐Neto, Carlos

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761979 Get It

Intraoperatively Diagnosed Facial Schwannoma: A Multicenter Study of Incidence, Management, and Proposed Preoperative Imaging Protocol
Lewis, Daniel J. , Plitt, Aaron , Neff, Brian A., Hammerbeck-Ward, Charlotte , Driscoll, Colin L. W., Carlson, Matthew L. , Lloyd, Simon , Freeman, Simon , Potter, Gillian , Link, Michael J., Hannan, Cathal John , Lewis, Daniel, Richardson, George E. , King, Andrew Thomas , Gompel, Jamie J. Van , Pathmanaban, Omar Nathan , Link, Michael J. , Rutherford, Scott

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761971 Get It

Evaluation of Eculizumab Use in Renal Transplant Recipients
Norville, Kathryn , Stephen, Jenise, Mead‐Harvey, Carolyn , Corey, Rebecca, Votruba, Cassandra , Votruba, Cassandra D

Mayo Clinic

Progress in Transplantation | March 20, 2023 | Volume: 33 | Issue: 2 | Pages: 162-167

10.1177/15269248231164163 | PMID 36940100 Get It

Introduction: Eculizumab is a monoclonal antibody that binds to complement protein C5, inhibiting complement-mediated thrombotic microangiopathy. It is approved for several indications including atypical hemolytic uremic syndrome. Additionally, eculizumab is used off-label for antibody-mediated rejection and C3 glomerulopathy in renal transplant recipients. Due to limited data available, the purpose of this study was to describe the use of eculizumab treatment in renal transplant recipients. Design: This retrospective single-center study evaluated the safety and efficacy of eculizumab for on- and off-label indications in renal transplant recipients. Adult renal transplant recipients receiving at least 1 dose of eculizumab posttransplant between October 2018 and September 2021 were included. The primary outcome evaluated was graft failure in patients treated with eculizumab. Results: Forty-seven patients were included in analysis. The median age at eculizumab initiation was 51 years [IQR 38-60], with 55% being female. Indications for eculizumab included atypical hemolytic uremic syndrome/thrombotic microangiopathy (63.8%), antibody-mediated rejection (27.7%), C3 glomerulopathy (4.3%), and other (4.3%). Graft failure occurred in 10 patients (21.3%) with a median of 2.4 weeks [IQR 0.5-23.3] from transplant to graft failure. At last follow-up (median 56.1 weeks), 44 (93.6%) patients were alive. After eculizumab initiation, renal function improved at 1 week, 1 month, and last follow-up. Conclusion: Eculizumab treatment demonstrated a benefit on graft and patient survival compared to reported incidence in thrombotic microangiopathy and antibody-mediated rejection. Due to the small sample size and retrospective design, further research is warranted to confirm these results.
Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
Moua, Teng , Valenzuela, C, Wuyts, W.A., Miede, Corinna, Lievens, D., Bonella, Francesco , Okamoto, Masaki , Tomassetti, Sara , Valenzuela, C, Bendstrup, Elisabeth

Mayo Clinic

Pneumologie | March 20, 2023 | Volume: 77 | Issue: S 01 | Pages: S57-S57

10.1055/s-0043-1761002 Get It

Patient-centered development ofEmbrace Pain: an online acceptance and commitment therapy intervention for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy
Graaf, Daniëlle L. van de , Smeets, Tom , Trompetter, Hester R. , Baars-Seebregts, Aafke, van de Graaf, Daniëlle L , Solberg Nes, Lise , Lee, Marije Liesbeth van der , Børøsund, Elin , Nes, Lise Solberg , Schreurs, Karlein M G , Mols, Floortje

Mayo Clinic

Acta Oncologica | March 20, 2023 | Volume: 62 | Issue: 7 | Pages: 676-688

10.1080/0284186x.2023.2187260 | PMID 36939672 Get It

HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy
Joehlin‐Price, Amy , Komforti, Miglena K. , Ladwig, Nicholas R. , Devine, Patrick J., Hoyle, Carrie, McCoy, Lauren, Sprague, Cathy, Astbury, Caroline , Chen, Yunn‐Yi , Garg, Karuna , Devine, Patrick, McCoy, Lauren, Hoda, Raza S.

Mayo Clinic

American Journal of Surgical Pathology | March 20, 2023 | Volume: 47 | Issue: 5 | Pages: 580-588

10.1097/pas.0000000000002030 | PMID 36939053 Get It

Among gynecologic cancers, uterine serous carcinoma (USC) has been shown to be human epidermal growth factor receptor 2 (HER2) amplified and trastuzumab has been included in the recent National Comprehensive Cancer Network (NCCN) guidelines for treatment of advanced stage or recurrent USC with HER2 overexpression/amplification. There is limited literature suggesting that a subset of high-grade endometrioid carcinomas with aberrant p53 expression may also be HER2 amplified and these patients could benefit from the addition of targeted therapy. We identified 59 p53-aberrant (mismatch repair proficient) FIGO 3 endometrioid carcinomas of the uterus. HER2 immunohistochemistry was performed in all 59 tumors and HER2 fluorescence in situ hybridization (FISH) was performed in 52 of the 59 cases. Four of the 59 cases were HER2 3+ by immunohistochemistry (6.7%), using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2007, 2013, and 2018 criteria. HER2 FISH was performed in 3 of the 4 cases and was amplified in all 3. Nine, 8, and 7 tumors showed 2+ HER2 staining when applying 2018, 2013, and 2007 criteria, respectively, FISH was performed in 7 tumors and none were amplified. An additional 4 cases did not perfectly meet the 2018 ASCO/CAP criteria but were assigned a score of 2+, none were amplified by HER2 FISH. The remaining 42 cases showed 1+ or no staining for HER2, FISH was successfully performed in 38 tumors and none showed amplification. Approximately half of the tumors fulfilled criteria for HER2-low or HER2-very low (10 HER2-low and 20 HER2-very low). Our data shows that a subset of p53-aberrant high-grade endometrial endometrioid carcinoma express HER2 and these patients may benefit from the addition of targeted therapy. The role of targeted therapy in HER2-low gynecologic carcinoma is currently unexplored.
Female and low‐ and middle‐income authorship trends in high‐impact ENT journals (2011–2020)
Jashek‐Ahmed, Farizeh , Daudu, Davina , Heer, Baveena, Ali, Hawa M. , Wiedermann, Joshua P. , Seguya, Amina , (globalohns.org), Members of the Global OHNS Initiative, Ali, Hawa , Wiedermann, Joshua , (globalohns.org), Members of the Global OHNS Initiative

Mayo Clinic

Laryngoscope Investigative Otolaryngology | March 20, 2023 | Volume: 8 | Issue: 2 | Pages: 417-425

10.1002/lio2.1044 | PMID 37090877 Get It

AbstractIntroductionDespite a recent drive to increase diversity, the global academic workforce is skewed in favor of authors from high‐income countries, and women are under‐represented in the published medical literature.ObjectivesTo explore the trends in authorship of three high‐impact otolaryngology journals over a ten‐year period (2011–2020).MethodsJournals selected: JAMA Otolaryngology–Head and Neck Surgery, The Laryngoscope and Rhinology. Articles were reviewed from four issues per journal per year, and data was collected on: time of publication; subspeciality; number of authors; sex of first and last authors; country of practice of first author and country where each study was conducted. Trends were examined though univariate and multivariate logistic regression models.Results2998 articles were included. 93.9% of first authors and 94.2% of studies were from high‐income countries.Women were first authors in 31.5% (n = 912) and senior authors in 18.4% (n = 524) of articles. Female first authorship significantly increased between 2011 and 2020 however female senior authorship remained the same. There have been no significant changes in the proportion of published articles from low‐and middle‐income countries (LMIC) over time (p = .65). Amongst the LMIC articles, 72% came from Brazil, Turkey or China and there were no published papers from countries with a low‐income economy (gross national income per capita of $1085 or less).ConclusionsAlthough female first authorship has increased in the last decade, there has been minimal other demographic change in authorship over this time. High‐impact otolaryngology journals poorly represent academia in low‐and‐middle income countries. There is a need for increased advocacy promoting gender and geographical research equity in academic medicine.Level of EvidenceIII.
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, Jamie M. , Helzer, Kyle T. , Stahlfeld, Charlotte N. , Jiang, Dawei , Singh, Anupama , Kaufmann, Katherine R. , Niles, David J. , Héninger, Erika , Rydzewski, Nicholas R. , Wang, Liguo , Wang, Liewei , Yang, Rendong , Ren, Yanan , Kyriakopoulos, Christos E. , Slovin, Susan F. , Soule, Howard R. , Zhao, Shuang G. , Cai, Weibo , Dehm, Scott M. , Lang, Joshua M. , Engle, Jonathan W , Huang, Peng , Kyriakopoulos, Christos E , Slovin, Susan F , Soule, Howard R , Zhao, Shuang G , Kohli, Manish , Tagawa, Scott T , Cai, Weibo , Dehm, Scott M , Lang, Joshua M , Wang, Liguo , Engle, Jonathan W. , Kohli, Manish , Tagawa, Scott T.

Mayo Clinic

Clinical Cancer Research | March 20, 2023 | Volume: 29 | Issue: 12 | Pages: 2324-2335

10.1158/1078-0432.ccr-22-1305 | PMID 36939530 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC). Experimental Design: TROP-2 gene (TACSTD2) expression and markers of treatment resistance from prostate biopsies were analyzed using data from four previously curated cohorts of mCRPC (n = 634) and the PROMOTE study (dbGaP accession phs001141.v1.p1, n = 88). EPCAM or TROP-2–positive circulating tumor cells (CTC) were captured from peripheral blood for comparison of protein (n = 15) and gene expression signatures of treatment resistance (n = 40). We assessed the efficacy of TROP-2–targeting agents in a mouse xenograft model generated from prostate cancer cell lines. Results: We demonstrated that TACSTD2 is expressed in mCRPC from luminal and basal tumors but at lower levels in patients with neuroendocrine prostate cancer. Patients previously treated with ARSI showed no significant difference in TACSTD2 expression, whereas patients with detectable AR-V7 expression showed increased expression. We observed that TROP-2 can serve as a cell surface target for isolating CTCs, which may serve as a predictive biomarker for ADCs. We also demonstrated that prostate cancer cell line xenografts can be targeted specifically by labeled anti–TROP-2 agents in vivo. Conclusions: These results support further studies on TROP-2 as a therapeutic and diagnostic target for mCRPC.
Mass spectrometry‐based proteomic profiling of sonicate fluid differentiates Staphylococcus aureus periprosthetic joint infection from non‐infectious failure: A pilot study
Fisher, Cody R. , Mangalaparthi, Kiran K. , Greenwood‐Quaintance, Kerryl E. , Abdel, Matthew P. , Pandey, Akhilesh , Patel, Robin , Patel, Robin , Pandey, Akhilesh , Abdel, Matthew P , Fisher, Cody , Greenwood-Quaintance, Kerryl

Mayo Clinic

PROTEOMICS – Clinical Applications | March 20, 2023 | Volume: 17 | Issue: 5 | Pages: No page available

10.1002/prca.202200071 | PMID 36938941 Get It

AbstractPurposeThis pilot study aimed to use proteomic profiling of sonicate fluid samples to compare host response during Staphylococcus aureus‐associated periprosthetic joint infection (PJI) and non‐infected arthroplasty failure (NIAF) and identify potential novel biomarkers differentiating the two.Experimental designIn this pilot study, eight sonicate fluid samples (four from NIAF and four from S. aureus PJI) were studied. Samples were reduced, alkylated, and trypsinized overnight, followed by analysis using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) on a high‐resolution Orbitrap Eclipse mass spectrometer. MaxQuant software suite was used for protein identification, filtering, and label‐free quantitation.ResultsPrincipal component analysis of the identified proteins clearly separated S. aureus PJI and NIAF samples. Overall, 810 proteins were identified based on their detection in at least three out of four samples from each group; 35 statistically significant differentially abundant proteins (DAPs) were found (two‐sample t‐test p‐values ≤0.05 and log2fold‐change values ≥2 or ≤−2). Gene ontology pathway analysis found that microbial defense responses, specifically those related to neutrophil activation, to be increased in S. aureus PJI compared to NIAF samples.Conclusion and clinical relevanceProteomic profiling of sonicate fluid using LC‐MS/MS differentiated S. aureus PJI and NIAF in this pilot study. Further work is needed using a larger sample size and including non‐S. aureus PJI and a diversty of NIAF‐types.
Focal epilepsies: Update on diagnosis and classification
Nascimento, Fábio A. , Peters, Jurriaan M. , Bensalem‐Owen, Meriem, Rampp, Stefan , Wirrell, Elaine , Blümcke, Ingmar , Tatum, William O. , Rampp, Stefan , Wirrell, Elaine C , Blümcke, Ingmar , Tatum, William O , Beniczky, Sándor , Nascimento, Fábio A , Friedman, Daniel , Cendes, Fernando

Mayo Clinic

Epileptic Disorders | March 20, 2023 | Volume: 25 | Issue: 1 | Pages: 1-17

10.1002/epd2.20045 | PMID 36938903 Get It

AbstractCorrectly diagnosing and classifying seizures and epilepsies is paramount to ensure the delivery of optimal care to patients with epilepsy. Focal seizures, defined as those that originate within networks limited to one hemisphere, are primarily subdivided into focal aware, focal impaired awareness, and focal to bilateral tonic–clonic seizures. Focal epilepsies account for most epilepsy cases both in children and adults. In children, focal epilepsies are typically subdivided in three groups: self‐limited focal epilepsy syndromes (e.g., self‐limited epilepsy with centrotemporal spikes), focal epilepsy of unknown cause but which do not meet criteria for a self‐limited focal epilepsy syndrome, and focal epilepsy of known cause (e.g., structural lesions—developmental or acquired). In adults, focal epilepsies are often acquired and may be caused by a structural lesion such as stroke, infection and traumatic brain injury, or brain tumors, vascular malformations, metabolic disorders, autoimmune, and/or genetic causes. In addition to seizure semiology, neuroimaging, neurophysiology, and neuropathology constitute the cornerstones of a diagnostic evaluation. Patients with focal epilepsy who become drug‐resistant should promptly undergo assessment in an epilepsy center. After excluding pseudo‐resistance, these patients should be considered for presurgical evaluation as a means to identify the location and extent of the epileptogenic zone and assess their candidacy for a surgical procedure. The goal of this seminar in epileptology is to summarize clinically relevant information concerning focal epilepsies. This contributes to the ILAE's mission to ensure that worldwide healthcare professionals, patients, and caregivers continue to have access to high‐quality educational resources concerning epilepsy.